Preliminary Results Year Ended December 2011

John Dawson – Chief Executive Richard Wright – Finance Director

March 2012

2

2011 Highlights Three acquisitions completed with annualised revenue of £4.7m

Good growth in promoted products

Hydromol (25%) Oncology (10%)

Total sales down £3.9m against Deltacortril fall of £8.8m Total sales £46.0m (2010: £49.9m) Deltacortril sales £4.7m (2010: £13.5m)

PBT £10.7m (2010 £12.9m) Excluding Deltacortril £7.5m (2010: £5.4m)

Strong free cash flow of £8.4m

Strong balance sheet with gearing at 1.4 times EBITDA

Full year dividend increased by 32% to 0.75p (2010: 0.57p )

Company Background and Business Model

3

4 4

Background to Alliance

Started in 1998 as a speciality pharma company

Profitable, cash generative, dividend paying with low gearing

Proven business model focusing on acquisition of mature niche medicines with limited competition

Reinforced by selective promotional activity to deliver organic growth

Virtual model, with manufacturing, storage, logistics and sales forces outsourced

Sales mainly in UK, but also into 20+ other countries

Strong track record of 21 acquisitions in 14 years building up a portfolio of over 50 products

5

Niche brands that have stood the test of time

Product Life-cycle

Development Biotechs • development risk +++

In-patent • high price/short life • big Pharma • heavy marketing • volume risk ++

Higher volume – generics • very price competitive • price risk ++ Lower volumes – no generics

Launch Patent Expiry

- limited or no competition - 10+ years out of patent - stable sales - low risk

Time Cash

6 6

Longevity of niche prescription brands

Product 2011 Sales Launched By Launch

Date Alliance Since Description

Nu-Seals £5.3m Lilly 1978 2002 Low dose aspirin for prevention of heart attacks and strokes

Deltacortril £4.7m Pfizer 1957 2006 Steroid to control immune system in a variety of conditions

Forceval £4.2m Unigreg 1970 2004 Complete supplement of micro-nutrients

ImmuCyst £4.1m Cambridge Labs 2001 2010 Immunotherapy for non muscle invasive bladder cancer

Hydromol £3.6m Quinoderm 1987 2006 Range of emollient products used in the management of eczema and other dry skin conditions

Syntocinon/ Syntometrine £2.4m Sandoz 1956 1998/

2006 Childbirth: assist labour/prevent haemorrhage after delivery

Xenazine / Nitoman £2.3m Roche 1971 2010 Treatment for the alleviation of a wide range of hyperkinetic

movement disorders (e.g. chorea in Huntington’s disease)

Buccastem £2.1m Reckitt & Colman 1987 2009 Buccal tablet for treatment of nausea and vomiting

Toxicology product £1.5m Berk

Pharmaceuticals 1991 2010 Toxicology product sold into Government stockpile on a 2½ year cycle

Vitamin E £1.4m Roche 1989 2010 Only licensed liquid formulation treatment for correction of Vitamin E deficiency available in the UK

Average age 33 years

7 7

Sustainability of sales from non-promoted products

Like for like sales of non-promoted products*,indexed to 100 at January 2003

0

50

100

150

200

Jan-0

3Ju

l-03

Jan-0

4Ju

l-04

Jan-0

5Ju

l-05

Jan-0

6Ju

l-06

Jan-0

7Ju

l-07

Jan-0

8Ju

l-08

Jan-0

9Ju

l-09

Jan-1

0Ju

l-10

Jan-1

1Ju

l-11

Inde

xed

to 1

00 a

t Jan

03

Demonstrates sustainability of sales over 9 year period

3.5% average annual growth rate

*Excludes Deltacortril

8

Deltacortril: a special case Commercial management in a multi-source market

*Illustrative

0

2

4

6

8

10

12

14

16

2007 2008 2009 2010 2011 2012*

£m

Deltacortril sales

9

Risk reduction through diversity – over 50 products

Hydromol7.5%Oncology

10.4%

Nu-Seals11.1%

Deltacortril9.8%

Forceval8.8%

Other (40+ products)

32.3%

Toxicology Product3.1%

Vitamin E3.0%

Xenazine4.7%

Buccastem4.4%

Syntocinon / Syntometrine

5.1%

Pro forma 2011 revenue segmentation

Shaded = promoted

10

Selective promotion when economically justified

ImmuCyst • Immunotherapy for non-

muscle-invasive bladder cancer

• Promoted using bespoke contract field force

• Sales currently £4.1m pa Gelclair • Biofilm product for oral

mucositis associated with cancer therapies

• Sales currently £0.9m

Hydromol • Range of emollients for

remission of eczema • Acquired from Ferndale Labs

in 2006 • Using bespoke contract field

force covering hospital and general practice

• Grown from £0.9m to £3.6m and still growing

2011 Results

11

12

2011 results – summary

Sales £46.0m (2010: £49.9m)

Operating profit* £12.3m (2010: £18.7m)

Pre-tax profit* £10.7m (2010: £16.4m)

Adjusted basic EPS 3.62p (2010: 5.07p)

Free cash flow £8.4m (2010: £12.3m)

Net bank debt £18.4m (2010: £17.0m), with gearing at 1.4 times EBITDA

Final dividend proposed up 25% to 0.50p

Total dividend up 32% to 0.75p

*Before exceptional items

13 13

2011 Sales movements

2011 £m

2010 £m

Change £m

Hydromol Growth of 25% 3.6 2.9 +0.7

Oncology LFL growth of 10% plus full year of sales 5.0 3.9 +1.1

Nu-Seals Market share gain offset by price decrease 5.3 4.8 +0.5

Toxicology product Lowest point of 2.5 year replacement cycle 1.5 3.2 (1.7)

Other Cambridge Labs Full year effect 6.8 4.6 +2.2

2011 Acquisitions Annualised sales of £4.7m 1.6 - +1.6

Deltacortril Additional competition and reduction in market size

4.7 13.5 (8.8)

Other 3% growth from core non-promoted brands 17.5 17.0 +0.5

Total 46.0 49.9 (3.9)

Sales history

14

-

10.0

20.0

30.0

40.0

50.0

60.0

Sal

es £

m

Underlying Deltacortril* 10 months annualised ** excluding Deltacortril

Five year compound annual growth rate to 2011:

9% organic (5%**)

13% acquisitions

22% combined (19%**)

Profit history

-

2

4

6

8

10

12

14

16

18

04/05 2005* 2006 2007 2008 2009 2010 2011

Ann

ual /

Ann

ualis

ed p

re-ta

x pr

ofit

befo

re

exce

ptio

nal i

tem

s £m

Underlying Deltacortril * 10 months annualised

15

16

Income Statement £’m 2011 2010

Sales 46.0 49.9

Gross profit 24.5 30.4

Gross margin % 53.3% 60.9%

Operating costs (11.4) (10.9)

Amortisation (0.7) (0.8)

Operating profit (pre-exceptionals) 12.3 18.7

Operating profit % 26.8% 37.5%

Financing costs (1.6) (2.3)

Adjusted PBT (pre-exceptionals) 10.7 16.4

Exceptional items - (3.5)

Reported PBT 10.7 12.9

Tax (2.1) (3.9)

Profit After Tax 8.6 9.0

Basic EPS 3.63p 3.96p

Adjusted EPS 3.63p 5.07p

Corporation tax

£000 2011 2010

PBT 10,712 12,872

Tax charge 2,076 3,918

Effective rate in income statement 19.4% 30.4%

Remove prior year adjustments 225 (215)

Remove impact of reduction in UK tax rate on deferred tax liability

314 141

Underlying tax charge 2,615 3,844

Underlying effective rate in income statement 24.4% 29.9%

Cash tax payable in respect of 2011 2,046

Effective cash tax rate 19.1%

17

18

Cash Flow

£’m 2011 2010

Operating profit 12.3 18.7 Depreciation and amortisation 1.0 1.0 Working capital (1.8) (1.8) Cash flow from trading 11.5 17.9 Interest (1.5) (2.0) Refinancing - (1.5) Capital expenditure (0.1) (0.9) Tax paid (1.5) (1.3) Free cash flow 8.4 12.2 Acquisitions (8.6) (14.3) Equity issued 0.2 7.5 Dividend (1.4) (0.7) Underlying debt (increase)/decrease (1.4) 4.7

19

Balance Sheet

£’m Dec 11 Dec 10 Change Intangibles: Product licences 66.1 60.3 +5.8

Inventories 5.7 4.5 +1.2

Trade and other receivables 8.7 9.7 (1.0)

Trade and other payables (8.4) (11.9) +3.5

Taxes (current and deferred) (5.1) (4.5) (0.4)

Other net assets - (0.1) (0.1)

Net cash 1.1 2.0 (0.9)

Bank loans (19.5) (19.0) (0.5)

Net bank debt (18.4) (17.0) (1.4) Convertible loan stock (4.5) (4.9) +0.4 Equity 44.1 36.1 +8.0

Outlook

20

21

Growth outlook - trading

Hydromol 2011 sales of £3.6m

25% growth rate

Oncology 2011 sales of £5.0m

10% growth rate (LFL)

looking for further products to add to portfolio

Forceval China good medium term growth potential

Non-promoted products provide modest growth

Toxicology product 2012/13 tender won

Latest acquisitions showing promise

Buccastem nausea and vomiting

Anbesol mouth pain

Ashton & Parsons Infant Powders teething and colic

Rizuderm severe acne

Quinoderm moderate acne

22 22

Acquisitions in 2011

Anbesol and Ashton & Parsons from Reckitt Benckiser for £2.6m in April Anbesol

Relief of mouth pain, sales £1.3m pa Ashton & Parsons Infant Powders

Teething pain and associated colic, sales £0.8m pa, production issues to resolve

Six products from Beacon Pharmaceuticals for £2.4m in September Total sales of £2m, gross margin £0.9m Main product is Rizuderm (isotretinoin), for treatment of severe acne

Quinoderm and Ceanel from Ferndale for £1.5m in December Combined sales of around £0.6m Quinoderm is an OTC acne treatment and Ceanel is a shampoo treatment for scalp psoriasis

£13.5m of bank facility available to fund further acquisitions

23 23

Acquisitions – track record

16 Brands Fostering

Arrangement

Nu-Seals £9.0m

Symmetrel & Slow K

£4.0m

Distamine £0.5m

Alphaderm Aquadrate

£2.1m

Forceval £7.0m

Periostat £1.8m

4 Derma Brands £0.9m

Dermamist £0.26m

Hydromol £3.3m

4 Brands

£2.1m

C A R A D E R M

1998

2001

Atarax

Deltacortril Terracortrill

£1.0m

Forceval China

£1.95m

Permitabs £0.8m

Syntometrine

£2.0m

Pavacol D £0.6m

• 21 deals in 14 years

• Every year since 2006

Buccastem Timodine

£7.5m

Cambridge £14.3-16.4m

Anbesol Ashton &

Parsons £2.6m

1999

2002

2004

2006

2007

2008

2009

2010

2011

Rizuderm + 5 Products

£2.4m

Quinoderm Ceanel £1.5m

24 24

Summary

Robust business model Strong underlying growth

Stability of finance Growing size of portfolio diversifies risk Good capacity for future acquisitions – actively evaluating opportunities

25 25

Appendices

26 26

Top 20 Investors: 5 March 2012 Holder / Fund Manager No. of Shares % Holding

Director & Related 67,635,893 28.13%

Nigel Wray 33,871,995 14.11%

Aviva Investors Global Services 23,716,755 9.88%

MVM Life Science Partners 19,300,000 8.03%

Slater Investments 9,145,000 3.81%

Artemis Fund Managers 7,948,549 3.31%

LGT Capital Management 7,196,071 3.00%

Investec Asset Management 6,750,000 2.81%

Hargreave Hale 6,180,750 2.57%

Brown Shipley Asset Management 5,996,624 2.50%

BlackRock Investment Management (UK) Limited 5,321,500 2.22%

Henderson Global Investors 4,200,450 1.75%

Barclays Wealth 3,982,232 1.66%

Cavendish Asset Management 2,944,000 1.23%

Seymour Pierce 2,699,119 1.12%

Hargreaves Lansdown Asset Management 2,276,044 0.95%

TD Direct Investing 2,244,471 0.93%

Redmayne Bentley Stockbrokers 2,004,489 0.84%

NCL Smith & Williamson Investments 1,914,000 0.80%

Adam & Co 1,562,720 0.65%

Total No of Share Owners - 845 No of Shares in Issue – 240,067,284

27 27

Convertible Unsecured Loan Stock

£4.4m of CULS remaining, paying 8% coupon Was £7.5m, but £3.1m converted since March 2010

Convertible at the option of the holders at any time up to 30 November 2013 at 21 pence per share

20.9m additional shares if all £4.4m convert

Otherwise redeemed at par

Publicly traded with a current price c. £1.40*

Held mainly by a small number of income funds

*As at 14 March 2012

28 28

Board members

Richard Wright, Finance Director: MA, Chartered Accountant, >20 years experience across various industries, joined 2007

Michael Gatenby, Non Executive Chairman MA. FCA ex-director of Hill Samuel and Co, ex-Vice Chairman of Charterhouse Bank. Holds a number of non executive directorships

John Dawson, CEO Pharmacist, MSc Finance; > 40yrs sector experience, founder of Alliance

Andrew Smith, Non Executive Director Senior positions held at SmithKline Beecham Pharmaceuticals, Diversified Health Systems Europe, Cerebrus plc and Parexel International

Thomas Casdagli, Non Executive Director Partner in MVM Life Science Partners, Chartered Accountant, graduated from Oxford in Molecular and Cellular Biochemistry, joined March 2009

Paul Ranson, Non Executive Director LL.B Barrister Solicitor. >25 years sector experience

Peter Butterfield, Director – UK Ex- UK Commercial Manager of Cambridge Laboratories Ltd, graduated from University of Edinburgh with BSc (Hons) specialising in neurotransmitter mechanisms.

Tony Booley, Director – International BSc Physiology, MBA, Chartered Marketer; 30yrs sector experience, with Alliance since 1998

29 29

Product portfolio BRAND NON-PROPRIETARY NAME USES

Acnisal 2% salicylic acid A medicated cleanser for the treatment and prevention of acne

Actidose-Aqua* activated charcoal An activated charcoal suspension for the emergency treatment of acute poisoning and drug overdose for a number of substances

Alphaderm hydrocortisone and urea An anti-inflammatory and hydrating cream used in the treatment of inflammatory dermatoses such as eczema and psoriasis

Anbesol Adult Strength Gel

lidocaine hydrochloride 2% chlorocresol 0.1% cetylpyridinium chloride 0.02%

For the temporary relief of pain caused by recurrent mouth ulcers and denture irritation

Anbesol Liquid lidocaine hydrochloride 0.9% chlorocresol 0.1% cetylpyridinium chloride 0.02%

For the temporary relief of pain caused by recurrent mouth ulcers, denture irritation and teething

Anbesol Teething Gel lidocaine hydrochloride 1% chlorocresol 0.1% cetylpyridinium chloride 0.02%

For the temporary relief of pain caused by recurrent mouth ulcers, denture irritation and teething

Ashton and Parsons tincture of matricaria This is a herbal product traditionally used in infants for the symptomatic relief of pain and gastric upset associated with teething

Aquadrate 10% urea A hydrating cream used in the treatment of dry, scaling and itchy skin disorders.

Including: ichthyosis and hyperkeratotic skin conditions associated with atopic eczema, xeroderma, iasteatosis and other chronic dry skin conditions

Atarax hydroxyzine hydrochloride For pruritus (itching) associated with acute and chronic urticaria in children and adults. Also for anxiety in adults

Buccastem & Buccastem M

prochlorperazine maleate A prescription treatment for nausea and vomiting, and for symptomatic treatment of other conditions such as vertigo. As an OTC product Buccastem M is used by migraine sufferers. It comes in a special buccal tablet formulation which adheres to the gum and releases the drug over one to two hours. This has a particular advantage as vomiting patients may encounter difficulties taking tablets orally

Cafergot* ergotamine tartrate and caffeine For the management of acute attacks of migraine headache in patients who have

not responded to simple analgesics

30 30

Product portfolio BRAND NON-PROPRIETARY NAME USES

Calcium Sandoz* calcium glubionate and calcium lactobionate

A calcium supplement used to maintain calcium levels. It is given in neonatal hypocalcaemia. It may help to replace lost calcium and reduce the risk of broken bones in elderly patients with osteoporosis.

Ceanel Concentrate

cetrimide undecenoic Acid

A clear, viscous, golden-yellow coloured liquid, used as an adjunct in the management psoriasis of the scalp, seborrhoeic dermatitis, dandruff-psoriasis of the trunk and limbs.

Deltacortril prednisolone Gastro-resistant tablets. Used for a wide range of disorders in which systemic

corticosteroids are indicated, including allergies, arteritis, rheumatic fever, rheumatic disorders, autoimmune disorders etc

Dermamist white soft paraffin Treatment of dry skin conditions including eczema, ichthyosis and pruritus in the elderly

Deseril*

methysergide Used for the prevention of migraine in patients who have not responded to alternative therapies. It is also used in the management of diarrhoea associated with carcinoid disease.

Dicobalt Edetate

dicobalt edetate Dicobalt injection is a specific antidote for acute cyanide poisoning. In view of the difficulty of certain diagnosis in emergency situations, it is recommended that Dicobalt Edetate only be given when the patient is tending to lose or has lost consciousness.

Distamine

penicillamine A disease modifying antirheumatic drug (DMARD) used for the treatment of rheumatoid arthritis (not osteoarthritis), Wilson's disease (toxic accumulation of copper), lead poisoning and cystinuria (formation of cystine stones in the kidneys).

Edrophonium* edrophonium chloride Myasthenia gravis, as a diagnostic test; to distinguish between overdosage and

underdosage of cholinergic drugs in myasthenic patients; diagnosis of suspected ‘dual block’; antagonist to non-depolarising neuromuscular blockade.

Forceval

multivitamin and mineral preparation

Capsules containing 24 essential vitamins and minerals (22 in the Junior capsules). Available on prescription unlike other preparations for use in patients with nutritional deficits due to disease e.g. AIDS, cancer, inflammatory bowel disease, or on restricted diets e.g. food intolerances, galactosaemia.

31 31

Product portfolio BRAND NON-PROPRIETARY NAME USES

Gelclair*

polyvinylpyrrolidone A viscous gel specially formulated to aid the management of lesions of the oral mucosa. It forms a protective film that, by adhering to the mucosa of the oropharyngeal cavity, can prevent further irritations thus contributing to the rapid relief of pain.

Hydromol Cream sodium pyrrolidone carboxylate 2.5% Cream for the treatment of dry skin conditions including dermatitis, eczema, ichthyosis and senile pruritus

Hydromol Bath & Shower Emollient

light liquid paraffin (37.8%) and isopropyl myristate (13%)

For the treatment of dry skin conditions such as eczema, ichthyosis and senile pruritus

Hydromol Ointment Yellow soft paraffin (30%) and emulsifying wax (30%)

Ointment for moisturizing and softening dry skin. May be used as a soap substitute

Hydromol Intensive 10% urea A hydrating cream used in the treatment of dry, scaling and itchy skin disorders.

Including: ichthyosis and hyperkeratotic skin conditions associated with atopic eczema, xeroderma, iasteatosis and other chronic dry skin conditions

Hydromol HC Intensive

hydrocortisone and urea An anti-inflammatory and hydrating cream used in the treatment of inflammatory dermatoses such as eczema and psoriasis.

Hygroton chlortalidone A diuretic to treat mild to moderate hypertension and oedema. Also used for diabetes insipidus (excessive urination).

Immucyst*

bacillus of calmette and guérin Indicated for intra-vesicular use in the treatment and prophylaxis of primary or recurrent carcinoma in situ (CIS) of the urinary bladder, and for the prophylaxis following transurethral resection (TUR) of primary or recurrent stage Ta and/or T1 papillary tumours, or any combination thereof, regardless of antecedent intra-vesicular treatment.

Isocarboxazid* isocarboxazid For the treatment of the symptoms of depressive illness. (monoamine oxidase inhibitor)

Isoniazid* isoniazid

For all forms of pulmonary and extra-pulmonary tuberculosis.

Isotretinoin isotretinoin

For the treatment of severe forms of acne (such as nodular or conglobate acne or acne at risk of permanent scarring), resistant to adequate courses of standard therapy with systemic antibacterials and topical therapy

32 32

Product portfolio BRAND NON-PROPRIETARY NAME USES

Lysovir amantadine Used for the prevention and treatment of influenza A

Menadiol* menadiol diphospate (as menadiol sodium diphospate)

For the treatment of haemorrhage associated with a low blood level of prothrombin or factor vii. The main indication is obstructive jaundice (before and after surgery)

Meted 3% salicylic acid & 5% sulphur A medicated shampoo for the treatment of seborrhoeic dermatitis, scalp dermatitis and dandruff. Relieves the itching, irritation, erythema and flaking

Metopirone*

Metyrapone Used in the diagnosis of certain problems of the adrenal glands. It is also used for the management of Cushing's syndrome (a rare disorder, mainly of females, characterized by a moonface, obesity and excessive growth of hair) and oedema.

Molipaint potassium hydrochloride For the treatment of molluscum contagiosum

Naseptin chlorhexidine neomycin An antimicrobial cream for inside the nose. It is used for eradicating staphylococcus infections in the nose.

Neostigmine Bromide

neostigmine bromide Myasthenia gravis; paralytic ileus; post-operative urinary retention. Neostigmine Bromide Tablets are used mainly for the treatment of myasthenia gravis, a disease in which the muscles are weak and tire easily. They are also used when the normal movements of the intestine are absent and for the treatment of urinary retention after surgery.

Nu-Seals

aspirin, gastro-resistant tablets Low and standard dose aspirin with a protective coat to protect against GI side effects of aspirin. Low dose is used to prevent heart attacks and ischaemic strokes in patients with risk factors. Standard dose used for all aspirin indications except acute pain relief.

Occlusal 26% salicylic acid A topical solution for the treatment and prevention of common and planar warts.

Ondemet ondansetron hydrochloride dehydrate

For the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy, and for the prevention of post-operative nausea and vomiting (PONV).

Oxymetholone* oxymetholone Oral tablet formulation synthetic male homone, which enhances and repairs the

body tissue-building process as a treatment for aplastic and refractory anaemias

33 33

Product portfolio BRAND NON-PROPRIETARY NAME USES

Pavacol-D pholcodine A sugar free liquid for the symptomatic treatment of dry troublesome coughs.

Pentagastrin* pentagastrin Pentagastrin Injection BP is used for the diagnostic testing of gastric secretion.

Pentrax fractar 5 coal tar extract A shampoo for the treatment of seborrhoeic dermatitis, scalp dermatitis and

dandruff. Relieves the itching, irritation, erythema, flaking and scaling

Periostat doxycycline Subantimicrobial dose doxycycline used for the treatment of periodontitis. By

suppressing tissue destructive MMP enzymes, it has an anti-inflammatory rather than an antimicrobial action. Licensed in Europe through MRP

Permitabs potassium permanganate A mild antiseptic, used to clean and deodorise oozing, eczematous skin conditions and wounds

Phenytoin

phenytoin sodium For the control of status epilepticus of the tonic-clonic (grand mal type) and the prevention and treatment of seizures occurring during or following neurosurgery and/or severe head injury. Also used in the treatment of cardiac arrhythmias where first line therapy is not effective. It is of particular value when these are digitalis induced.

Procarbazine Capsules

procarbazine hydrochloride The main indication is Hodgkin's disease (lymphadenoma). Procarbazine may also be useful in other advanced lymphomata and a variety of solid tumours which have proved resistant to other forms of therapy.

Quinoderm Cream benzyl peroxide potassium hydroxyquinoline sulphate

A creamy white astringent vanishing cream for acne vulgaris, acne form eruptions and folliculitis.

Quinoderm Antibacterial Facewash

chlorhexidine gluconate cetrimide An antimicrobial soap substitute, designed to kill harmful bacteria found on the skin, to be used both morning and night.

Ranitidine

ranitidine hydrochloride For the treatment of duodenal ulcer, benign gastric ulcer, post-operative ulcer and of Zollinger-Ellison Syndrome. For the managements of conditions where reduction of gastric secretion and acid output is desirable, such as reflux oesphagitis. As prophylaxis against gastrointestinal haemorrhage from stress ulceration, recurrent haemorrhage and acid aspitaion (Medelson's Syndrome) before anaesthesia.

34 34

Product portfolio BRAND NON-PROPRIETARY NAME USES

Rogitine*

phentolamine Used in the diagnosis of phaeochromocytoma, a tumour of the adrenal gland and in the management of hypertensive episodes associated with phaeochromocytoma.

Sinthrome*

acenocoumarol An oral anticoagulant used in the treatment or prevention of thromboembolic disorders.

Slow-K*

potassium chloride A potassium supplement used to correct low potassium levels associated with disease, poor diet or other drug therapy.

Symmetrel*

amantadine Used in the treatment of Parkinson's disease and herpes zoster but only in those patients who you could expect to get a severe and painful rash. The syrup is also useful in the treatment and prevention of influenza type A.

Synacthen* tetracosactide Used in the diagnosis of adrenocortical insufficiency. Stimulates the formation of adrenal steroids (cortisol).

Synacthen Depot* tetracosactide – slow release A long acting formulation of Synacthen. In addition, it is used to treat various

inflammatory diseases including ulcerative colitis, rheumatoid arthritis, and osteoarthritis in short term use only.

Syntocinon*

oxytocin A synthetic form of the hormone oxytocin, used in the induction of labour, the management of missed and incomplete abortion and to stop excessive bleeding following delivery.

Syntometrine*

ergometrine maleate oxytocin A combination of oxytocin and ergometrine used during the last stage of childbirth of following delivery of the placenta to prevent or beat postpartum haemorrhage

Testosterone Enantate*

testosterone enantate Used for the treatment of andropause - males who have too little or no endogenous testosterone production.

Timodine

nystatin, 100,000 IU/g 3% w/w dimeticone 350 10%, hydrocortisone 0.5%w/w benzalkonium chloride solution 0.2% w/w

Anti-fungal and anti-bacterial skin cream used for treating inflamed and infected skin conditions in which the Candida albicans fungus is a factor. Uses include treatment of severe nappy rash, eczema and other dermatoses

35 35

Product portfolio

BRAND NON-PROPRIETARY NAME USES

Uniflu with Gregovite C*

caffeine, codeine, diphenhydramine, paracetamol, phenylephrine, vitamin C

Uniflu tablets and Gregovite C tablets. For the relief from the signs and symptoms of colds and flue

Valaciclovir

valaciclovir hydrochloride For the treatment of shingles (herpes zoster) infaction, the treatment and prophylaxis of herpes simplex infections of the skin and mucous membranes, including genital herpes. For the prophylaxis of cytomegalovirus (CMV) infection following renal transplantion

Vitamin E Suspension*

vitamin E suspension Vitamin E deficiency in malabsorption disorders. It is the only UK licensed liquid formulation treatment for the correction of Vitamin E malabsorption in conditions such as including Cystic Fibrosis (CF, primary indication) and chronic cholestasis. The active ingredient is tocopherol acetate, a synthetic form of vitamin E.

Xenazine*

tetrabenazine

Xenazine IR is used for alleviation of a wide range of hyperkinetic movement disorders such as chorea associated with Huntington’s disease (HD); tardive dyskinesias and tics associated with Tourettes syndrome. Tetrabenazine interferes with the normal action of dopamine to dampen neuro-transmission along motor pathways.

List contains licensed products * Brand names appearing throughout this report are trademarks either owned by and/or licensed to Alliance Pharmaceuticals Limited, with the exception of Actidose-Aqua, trademark of Paddock Labs Inc, Cafergot, Calcium Sandoz, Deseril, Hygroton, Metopirone, Rogitine, Slow-K, Synacthen, Synacthen Depot, Syntocinon, Syntometrine, trademarks of Novartis AG, Symmetrel, trademark of Endo Pharmacetucials Inc and Gregovite C, trademark of G R Lane, Gelclair trademark of Helsinn, ImmuCyst trademark of Sanofi Pasteur, Xenazine trademark of Biovail.